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Abstract
Background: Estrogen is a vital hormone that regulates many biological functions within the body. These include
roles in the development of the secondary sexual organs in both sexes, plus uterine angiogenesis and proliferation
during the menstrual cycle and pregnancy in women. The varied biological roles of estrogens in human health also
make them a therapeutic target for contraception, mitigation of the adverse effects of the menopause, and
treatment of estrogen-responsive tumours. In addition, endogenous (e.g. genetic variation) and external (e.g.
exposure to estrogen-like chemicals) factors are known to impact estrogen biology. To understand how these
multiple factors interact to determine an individual’s response to therapy is complex, and may be best approached
through a systems approach.
Methods: We present a physiologically-based pharmacokinetic model (PBPK) of estradiol, and validate it against
plasma kinetics in humans following intravenous and oral exposure. We extend this model by replacing the intrinsic
clearance term with: a detailed kinetic model of estrogen metabolism in the liver; or, a genome-scale model of liver
metabolism. Both models were validated by their ability to reproduce clinical data on estradiol exposure. We
hypothesise that the enhanced mechanistic information contained within these models will lead to more robust
predictions of the biological phenotype that emerges from the complex interactions between estrogens and the body.
Results: To demonstrate the utility of these models we examine the known drug-drug interactions between
phenytoin and oral estradiol. We are able to reproduce the approximate 50% reduction in area under the
concentration-time curve for estradiol associated with this interaction. Importantly, the inclusion of a genome-scale
metabolic model allows the prediction of this interaction without directly specifying it within the model. In addition,
we predict that PXR activation by drugs results in an enhanced ability of the liver to excrete glucose. This has
important implications for the relationship between drug treatment and metabolic syndrome.
Conclusions: We demonstrate how the novel coupling of PBPK models with genome-scale metabolic networks has
the potential to aid prediction of drug action, including both drug-drug interactions and changes to the metabolic
landscape that may predispose an individual to disease development.
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Background
Estradiol is a major endocrine hormone, and is respon-
sible for modulating multiple biological functionalities
throughout the human life cycle. Most notably, it plays a
central role in development of the reproductive organs,
and continue to be important in the reproductive cycle
throughout life [1]. During the menstrual cycle and
pregnancy estradiol plays a central role in uterine angio-
genesis and endometrial proliferation [2, 3]. Plasma con-
centrations of total estradiol vary through the menstrual
cycle (0.1-1 nM: [4, 5]), increasing steadily through preg-
nancy to reach approximately 100 nM at term [6].
Given the role of estradiol in core body functions, it is
perhaps not surprising that its level has been associated
with a number of disease states, and that estradiol-
mediated biology is a key therapeutic target. Elevated
plasma estrogens have been associated with protection
against cardiovascular disease [7], but also an increased risk
of breast cancer in post-menopausal women; a two-fold in-
crease in estradiol levels being associated with a 1.3-fold in-
crease in relative risk [8]. This carcinogenic effect is
probably mediated through a number of mechanisms, in-
cluding the generation of genotoxic catecholamine metabo-
lites [9] as well as the modulation of cell proliferation and
angiogenesis [2, 10].
Pharmacological agents are used to impact on both the
normal biological functions of estradiol (e.g. oral contra-
ceptives), and disease processes (e.g. anti-estrogenic can-
cer chemotherapy). The action of these therapies may be
altered through enzyme induction/inhibition elicited by
concomitantly administered drugs (e.g. anticonvulsants
such as phenytoin), environmental exposure to estrogen-
like endocrine disrupting chemicals [11], or ingestion of
phyto-estrogens in the diet [12]. In addition to pharmaco-
logical impacts on estrogen biology, there are a number of
genetic polymorphisms that may be of clinical importance.
For example, genetic variants within CYP19 and 17B–
HSD, important enzymes in the biosynthetic pathway of
estradiol, are associated with different circulating concen-
trations of estrogen [13, 14]. Likewise, polymorphisms
within the degradation pathways have been associated
with altered clearance of estrogens and the increased pro-
duction of the genotoxic catecholamines [15, 16].
Given the complex biological effects of estrogens, both
positive and negative, and the potential for gene/drug/en-
vironment interactions, the prediction of an individual’s
estrogen biological profile is complex. The related disci-
plines of computational and systems biology have devel-
oped to address questions such as this, allowing the
examination of large scale, complex networks to predict
the emergent biological response [17, 18]. A first stage in
the prediction of the biological phenotype elicited by any
chemical is the generation of robust disposition models,
most commonly as physiologically-based pharmacokinetic
models (PBPK [19]), which allow the prediction of
concentration-time curves for chemicals within the body.
Enhancing these models with mechanistically-detailed
models of biologically important hubs will further increase
their predictive power [17, 18].
In the current work, we extend the estrogen PBPK
model of Plowchalk and Teeguarden [20], increasing the
number of physiological compartments from seven to
18. We demonstrate that this extended model is able to
reproduce blood concentration-time curves for estradiol
in women following intravenous and oral exposures. We
expand this model, replacing the fitted intrinsic clear-
ance term with either a fully mechanistic model of estro-
gen metabolism within the liver, or a genome-scale
model of hepatic metabolism. To demonstrate the utility
of these models, we examine the impact of concomitant
exposure to the anticonvulsant phenytoin on blood es-
tradiol concentrations, demonstrating the ability to iden-
tify a clinically important drug-drug interaction (DDIs).
Methods
PBPK model structure
The PBPK model was created in COPASI v4.14 [21], and
was based upon the previously published human female
model of Plowchalk and Teeguarden [20]. The model pre-
dicts the disposition of estradiol (E2) through 16 tissue
compartments plus arterial and venous blood compart-
ments. Estradiol is synthesised within the compartment
{gonads}, and subject to extrahepatic clearance (CLeh)
and intrinsic clearance (CLint) from the compartments
{kidney} and {liver}, respectively. The overall structure of
the PBPK model is summarised in Fig. 1.
The original model comprised seven biological com-
partments: systemic plasma, poorly perfused tissue,
richly perfused tissue, pituitary, uterus, ovaries and liver.
In addition, an IV input compartment fed into the sys-
temic plasma, while an oral dosing compartment fed
into the liver. Here, venous and arterial blood compart-
ments are presented separately, along with 16 tissue
compartments, representing the major organs as defined
by Peters [22]. Rather than represent uterus and ovaries
separately, they are combined in the compartment {go-
nads}, which represents estradiol target tissues. This re-
flects a compromise between the desire to predict the
distribution of estradiol to target tissues, and the experi-
mental data to validate these predictions. With the ex-
ception of the liver and gonads, all compartments are
described as well-mixed, rapid equilibrium compart-
ments. The liver and uterus are treated as a
permeability-limited compartment with a separate tissue
blood compartment [20, 23]. Finally, compartments to
represent intravenous (i.v.) and oral (p.o.) delivery were
added to the model, inputting into the venous blood and
intestine compartments, respectively.
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As estradiol is an endogenous compound, an estrogen
biosynthesis reaction was added using mass action kinetics,
generating estradiol into the compartment {gonads_cells}.
The rate constant for this reaction was fitted to achieve a
steady-state blood concentration of 0.15 nM total estradiol,
consistent with the published literature [4, 5]. As estradiol
in the blood is approximately 98% bound to plasma pro-
teins, this equates to a free plasma concentration of ap-
proximately 0.003 nM [24].
An overview of the model structure is presented as Fig. 1,
while a full description of reaction parameters, balance
equations, global quantities and initial conditions is pre-
sented as Additional file 1. Generic physiological parame-
ters were taken from Bosgra [23] and estradiol-specific
parameters from Plowchalk and Teeguarden [20]. These
values were used to populate ordinary differential equations
as described by Peters [22]. The model is available for
download from BioModels [25] and www.LiverSystems.org.
PBPK-LiverODE model structure
A mechanistic model of estrogen metabolism within the
liver was created, hereafter denoted as LiverODE
(Additional file 1: Figure S3). The model comprises five
compartments: an input compartment representing ei-
ther medium or blood; an output compartment repre-
senting medium or bile; and three compartments
representing parts of the hepatocyte, namely apical
membrane space, basolateral membrane space, and cell
interior. Within the input compartment, estradiol is
present as E2 and E2free to represent diffusion-limited
access of estradiol to cells. E2free represents the bulk of
estradiol in the input compartment, while E2 represents
estradiol immediately bordering cells that can gain ac-
cess to the cell membrane and enter cells. This
diffusion-limited access is simulated through first order
kinetics, with a rate constant based upon previously used
estimates for chemical diffusion through medium [26].
Movement between compartments is through either pas-
sive diffusion or active transport. Within the hepatocyte,
estradiol is subject to sequestration through both spe-
cific (i.e. binding to the estrogen receptor) and non-
specific binding. Finally, estradiol undergoes a number
of metabolic conversions: it is interconverted with es-
trone through the actions of 17β-hydroxysteroid de-
hydrogenase 1 and 2 [27, 28]; both estradiol and estrone
are metabolised via CYP1A1 and CYP3A4 during Phase
I metabolism to form hydroxylated metabolites [29, 30];
the catecholamine metabolites from these reactions are
potent mutagens, and are readily deactivated through
the action of catechol-O-methyltransferase (COMT)
[31]; finally, both estradiol and estrone are metabolised
via SULT1E1, SULT2A1, UGT1A1, UGT1A3 and
UGT2B7 during Phase II metabolism [32] to form
sulphate and glucoronide conjugates, respectively. These
interconversions were selected as they represent the
major metabolic fates of estradiol in the liver, and robust
parameter values were available within the literature.
The LiverODE model was used to replace the intrinsic
clearance term (Clint) of the base PBPK model by mer-
ging of the {liver_plasma} compartment of the PBPK
model and the {medium} compartment of the LiverODE
model. This model is hereafter designated the PBPK-
LiverODE model. The model was validated against in
vitro data for estradiol clearance in primary human he-
patocytes (Additional file 1: Figure S4).
A full description, including overall structure, reaction
parameters, balance equations, global quantities and ini-
tial conditions, of the model is presented as Additional
file 1. The model is available for download from BioMo-
dels [25] and www.LiverSystems.org.
Fig. 1 Physiologically based Pharmacokinetic model for estradiol in
women. Distribution of estradiol between venous and arterial blood
compartments and 16 tissue compartments is represented. The liver
and gonads are represented as permeability-limited tissues, and all
other compartments well mixed. Estradiol enters the model through
synthesis into the gonads, oral dosing (p.o.) into the intestine, and
intravenous dosing (i.v.) into the venous blood. Estradiol is removed
from the model through extra-hepatic clearance (CLeh) from the
kidney, and intrinsic clearance from the liver. Intrinsic clearance is
modelled as either a single ODE (Clint), ODE-based model of liver
metabolism (LiverODE), or a genome-scale metabolic network (GSMN) as
described in text
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PBPK-GSMN model structure
The PBPK-GSMN model is based upon the PBPK
model, but with the Clint term replaced by a genome
scale metabolic network (GSMN). Briefly, GSMNs cap-
ture the total connectivity of a metabolic network within
a stoichiometric matrix, and coupled with constraint
based modelling approaches allow the examination of
metabolite flow through the entire network [18, 33].
Here, we used the Recon2 GSMN, the most comprehen-
sive general reconstruction of human metabolism, com-
prising 7440 reactions and 5764 metabolites [34].
To decrease the solution space for constraint based mod-
elling approaches additional constraints can be added, in-
creasing the robustness of predictions. Each reaction within
the GSMN is constrained by an upper bound (UB) and
lower bound (LB), representing the maximum and mini-
mum flux, respectively. Within Recon2, the maximum value
for a bound is 1000, with directionality reflected in the sign
of this value. Hence, a unidirectional forward reaction is de-
fined as 0,1000 (LB, UB), a unidirectional reverse reaction
(−1000,0), and a bidirectional reaction (−1000,1000). The
LB and UB can be reduced to further constrain the solution
space where additional biological information is present.
Here, these bounds were further constrained in two ways.
First, the physiological import-physiological export set was
used (PIPES; [35]), which only permits exchange of metabo-
lites normally present under physiological conditions. The
LB and UB for exchange reactions present within PIPES
were set to −1 and 1000, respectively, reflecting limited con-
sumption but unlimited production of these metabolites by
the cell. For all exchange reactions not present within
PIPES, UB and LB values were set to 0. Second, PIPES ex-
change reaction bounds were further constrained through
experimentally-derived nutrient production and consump-
tion rates, where available [36]. Jain et al. determined the
consumption and production rates for 219 metabolites
across the NCI60 cell culture collection. We assume that
the maximal values for consumption of each metabolite
across these immortal cell lines at least equals, and most
likely exceeds, that observed in vivo. We can therefore use
these values to set the LB for exchange reactions within the
PIPES. For example, the maximal rate of glucose depletion
from the medium across the NCI60 cell culture collection
was −1.723855 mmol/gDW/h, reflecting the maximal con-
sumption rate by cells. On this basis, the exchange reaction
for glucose (Recon2 ID: R_EX_glc_LPAREN_e_RPAREN)
was constrained with lower and upper bounds of −1.723855
and 1000, respectively.
Traditionally, constraint-based modelling approaches
have used the Biomass Reaction as an objective function
(R_Biomass_Reaction), which represents those constituents
required for cell division (e.g. ATP, amino acids, nucleotides
etc.) and thus can be used as a surrogate for cell division
[33].. While this is appropriate for many prokaryotic
models, where a main objective is to grow, it is inappropri-
ate for many eukaryotic cells. For example, liver cells are ef-
fectively senescent, but do retain a significant regenerative
capacity following liver injury. To represent this regenera-
tive capacity, a ‘Liver turnover’ constraint node was added,
which requires a minimum flux through the Biomass Reac-
tion (0.007). This further constrains the solution space to
represent the potential for cell division, but does not re-
quire the simulation to optimise for cell growth. Two ob-
jective functions for the flux balance analysis of the GSMN
are used within the current work, representing homeostatic
functions of the liver. First, we explore glucose-lactate
homeostasis: Lactate is constantly produced by red blood
cells through respiration, but blood levels must be main-
tained to prevent acidosis. The liver consumes lactate and
converts it to glucose, which is reflected by setting opti-
misation of external glucose production as the first
objective function. Glucose production (R_EX_glc_ LPARE-
N_e_RPAREN_) and lactate consumption (R_EX_lac_L_L-
PAREN_e_RPAREN_) fluxes are extracted from an
example flux distribution predicted by flux balance analysis
and used to predict blood concentrations of lactate and glu-
cose. Second, the role of the liver in estrogen and urea me-
tabolism is explored: Estrogen is an important endocrine
signalling molecule, while ammonia is produced through
the metabolism of amino acids throughout the body,
and converted to urea in the liver for subsequent elimin-
ation through the urine. Estradiol secretion is set as the sec-
ond objective function, representing the intrinsic clearance
of estradiol by the liver. Fluxes of interest are read from an
example flux distribution predicted by flux balance analysis:
excretion of urea (Recon2 ID: R_EX_Urea_LPAREN_e_R-
PAREN_), excretion of estradiol (Recon2 ID: R_EX_estra-
diol_LPAREN_e_RPAREN), formation of estrone sulphate
(Recon2 ID: R_ESTSULT), and formation of 2-OH estradiol
(Recon2 ID: R_RE3013R). Flux toward urea and estradiol
excretion are used to predict blood concentrations, flux to-
ward estrone sulphate measures a major metabolic fate of
estradiol, and flux toward 2-OH estradiol represents cat-
echolamine formation [33].
The PBPK and GSMN parts of the model were coupled
through the species ‘E2{liver_cells}’, representing free es-
tradiol within the hepatocyte. The model was constructed
in MuFINS [37], in which ODE-based networks are repre-
sented in Petri net (PN) formalism and linked to the
GSMN through special directed arcs using our quasi
steady-state Petri net (QSSPN) approach [38]. This allows
connection of metabolite (fluxes) between the PN and
GSMN parts of the model, as well as the setting of flux
bounds within the GSMN by the PN part of the model.
An advantage of the modelling approach used here is
the ability to dynamically alter flux bounds within the
GSMN [37]. This allows, for example, the exploration of
the impact of drug action on global metabolism. Here, we
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model drug-drug interactions occurring through activa-
tion of the pregnane X-receptor (PXR). PXR is a member
of the nuclear receptor superfamily, and is activated by a
large range of both endogenous and exogenous chemicals,
altering the expression of metabolic enzymes and mem-
brane transporters to respond to the stimulus [39]. Drug
interaction with PXR is represented by mass action kinet-
ics, with kon and koff rates set to reproduce the experi-
mentally determined affinity. Binding of an agonist with
PXR forms PXRL, the active form of PXR, which increases
the transcription of PXR target genes. Predicted concen-
tration of the encoded protein species vary from 111 nM
(basal transcription, no PXRL present) to 518 nM (max-
imal transcription, maximal level of PXRL). These protein
concentrations are used to inform the flux bounds for
mapped reactions [37, 38], with the Petri net place repre-
senting the encoded protein containing a comment that
sets the upper and lower reaction flux bounds for different
predicted protein concentrations: these range from 0,0.23
(lower bound, upper bound) at 100 nM protein to 0,0.63
at 550 nM protein, which are values that reproduce the
known rates of metabolism of estradiol in primary human
hepatocytes (Additional file 1).
PXR target genes were identified through a two-step
process: First, transcriptomic data from the Japanese Toxi-
cogenomics Program for primary human hepatocytes ex-
posed to 2.8μM, 14μM and 70μM of the classical PXR
ligand rifampicin for 2, 8 and 24 h [40] were extracted from
ArrayExpress (E-MTAB-798) [41]. Array analysis was per-
formed within the Bioconductor R suite with data pre-
processing using affy, and differential gene expression using
limma. Second, the list of differentially expressed genes was
further refined to include only direct targets of PXR. These
genes were identified through literature evidence of a direct
interaction via chromatin immunoprecipitation.
A cartoon of this model is presented as Additional file 1:
Figure S5, with a full description, including overall struc-
ture, reaction parameters, global quantities, initial condi-
tions, and literature evidence for PXR target genes also
presented as Additional file 1.
Virtual patient population
A virtual population was generated using the National
Health and Nutrition Examination Survey (NHANES)
2013–14 anthropometric data [42], representing a mod-
ern U.S. population. Briefly, anthropometric data was ex-
tracted for 1495 women aged 18–45 years inclusive.
Individual weight (Kg) and height (m) data are used to
calculate body mass index [weight/height2] and body
surface area [0.00718*weight0.425*(height*100)0.725].
These four parameters are used to predict individual
organ weights and blood flows using the equations pre-
sented in Bosgra et al. [23]. Summary statistics for the
NHANES cohort are presented as Additional file 1.
Model simulation and analysis
Both the PBPK and PBPK-LiverODE models were simu-
lated in COPASI [21], while the PBPK-GSMN model
was simulated using MuFINS [37]. Statistical analysis
was undertaken using GraphPad Prism v6.01 (GraphPad
Software Inc., La Jolla, USA). Datasets were compared
through a two-way ANOVA with Sidak’s multiple com-
parison test. The level of statistical significance was set a
priori at p < 0.05.
Results and discussion
Validation of models against clinical data
We first explored the ability of the three models to re-
produce known human responses to estradiol exposure.
First, we examined the ability of the models to repro-
duce the binding of estradiol to plasma proteins, specif-
ically albumin and steroid hormone binding protein
(SHBG). Second, we predicted the concentration-time
curve for plasma estradiol in humans following i.v. dos-
ing, and compared this to in vivo data. Third, concentra-
tions time curves for oral dosing were compared to
human data. Fourth, we explored how predicted com-
partment dispositions may reflect the in vivo situation.
Within the plasma compartment, the model predicts
concentrations of free estradiol, plus estradiol bound to al-
bumin and SHBG. Using a concentration of 25 nM estra-
diol, the distribution of estradiol within the plasma were
predicted for the original Plowchalk and Teeguarden PBPK
model and our expanded PBPK model (Fig. 2a). Modelled
free fractions are consistent between the two models (ap-
proximately 2%), and equivalent to the experimental data of
Sodergard et al. [43]. The predicted distribution of plasma
protein bound estradiol between albumin and SHBG is also
reproduced between the two models (approximately 58%
albumin-bound and 40% SHBG-bound), but differs from
the clinical data, which indicates approximately 52% of es-
tradiol is albumin-bound and 46% SHBG-bound. In the
Plowchalk and Teeguarden model, disassociation constants
of 17 μM and 1.5 nM were used for the interaction of estra-
diol with albumin and SHBG, respectively. In contrast, the
work of Sodergard et al. reports values of 23.8 μM and
3.18 nM, respectively [43]. When these values are used, free
estradiol remains at approximately 2%, but the resultant
distribution of bound estradiol is consistent with the clin-
ical data [44]. These latter values were adopted within the
PBPK model. When the PBPK model was expanded to in-
clude the mechanistic model of estradiol metabolism
(PBPK-LiverODE) or the GSMN (PBPK-GSMN) these per-
centage distributions were maintained (Fig. 2b).
Estrogens are clinically administered through a number
of routes, including intravenous, subcutaneous, oral, der-
mal and rectal. Here, i.v. and oral exposure routes have
been modelled, and validated against in vivo data. Kuhnz
et al. measured plasma levels of estradiol in young women
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following intravenous administration of a 0.3 mg bolus
[45]. Figure 3a, presents this in vivo data, plus simulations
for the virtual patient population. In each model, the
0.3 mg bolus was represented by an initial 1101nmoles of
estradiol in the {dose_IV} compartment. This was deliv-
ered to the {plasma_venous} compartment through a first
order mass action kinetics with a rate constant of 250 h−1,
which was essentially complete within 3 min. Entry to the
liver is permeability-limited, with a permeability rate of
1000 L.h−1 being used in the original of Plowchalk and
Teeguarden paper [20]. For the base PBPK model and the
PBPK-GSMN model this was replaced by uptake and ef-
flux rate constants of 1000 L.h−1 and 277.8 L.h−1, respect-
ively, reflecting a plasma:tissue coefficient of 3.6 [46]. For
the PBPK-LiverODE model, it was necessary to vary these
constants to best fit the clinical data, while maintaining a
plasma:tissue coefficient of 3.6: values of 150 L.h−1 and
41.7 L.h−1 were used, for uptake and efflux respectively.
This represents a 6.7-fold difference in the magnitude of
the rate constants between the two model systems. The
reason underlying this difference is unclear but may re-
flect parameter robustness in the LiverODE model. Kin-
etic parameters are derived from multiple in vitro systems,
while protein concentrations are measured using different
technical approaches. The parameters derived from these
approaches will each have their own precision level, and
the sum of these errors will influence the intrinsic clear-
ance of estradiol from the liver. As demonstrated in Fig. 3a,
all models were able to reproduce the clinical data with a
good degree of accuracy. Root mean square error (RMSE)
values decrease across the models, with RMSE values of
3.7, 1.2 and 0.9 for the PBPK, PBPK-LiverODE and PBPK-
GSMN models, respectively. The decrease in RMSE value
across the models is primarily driven by under prediction
at higher concentrations in the base PBPK model.
The ability of the models to reproduce oral dosing was
examined next. Lyrenas et al., exposed women to 2 mg
and 4 mg of radiolabelled estradiol, and then measured
plasma estradiol over the subsequent 50 h [47]. In each
model, the estradiol dose was represented by an initial
7342nmoles or 14685nmoles of estradiol (2 mg and 4 mg,
respectively) in the {dose_oral} compartment, and deliv-
ered to the {intestine} compartment through a first order
mass action kinetics with a rate constant of 0.025 h−1. In
addition to absorption into the intestine, estradiol within
the {dose_oral} compartment was depleted with a first
order rate constant of 0.01 h−1 to represent loss through
excretion. These values are consistent with the values used
by Plowchalk and Teeguarden [20]. As presented in
Fig. 3b, all three models are able to reproduce the clinical
data, demonstrating an initial rising phase comprising
drug absorption and clearance followed by a declining
phase comprising clearance only. Root mean square error
(RMSE) values decrease across the models, with RMSE
values 2 mg/4 mg oral dose of 0.113/0.175, 0.112/0.174
and 0.110/0.164 for the PBPK, PBPK-LiverODE and
PBPK-GSMN models, respectively. The decrease in RMSE
value across the models is, again, primarily driven by
under prediction at higher concentrations in the base
PBPK model. However, we note that there is considerable
variability in the clinical samples and as such comments
on data fit must be treated with caution.
To further explore the model performance, we calcu-
lated the maximal concentration (Cmax), time to Cmax
(Tmax) and the area under the concentration-time curve
(AUC∞) for each simulation (±s.d.) and compared them
to the respective in vivo data (Table 1). Prediction of
AUC for an i.v. bolus was extremely good for the base
PBPK model, and slightly under predicted by both the
PBP-LiverODE and PBPK-GSMN models. This under-
prediction is driven by under prediction of E2 plasma
concentration during the first 30 min after dosing. With
Fig. 2 Prediction of estradiol binding to plasma proteins. a Steady-state
binding of 25 nM estradiol to albumin and steroid hormone binding
globulin (SHBG) were simulated within the PBPK model and compared
to clinical data and the prediction of Plowchalk and Teeguarden. b
Steady-state binding of 25 nM estradiol to albumin and SHBG were
simulated for the PBPK model and compared to prediction from the
PBPK-LiverODE and PBPK-GSMN models, and experimental data of
Sodergard et al. [43]
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regards to oral exposures, we note that the model of
Plowchalk and Teeguraden was unable to accurately re-
produce oral dose data, with the Tmax values off by sev-
eral hours [20]. All three models presented here produce
good predictions of AUC, Tmax and Cmax following a
2 mg oral dose when compared to the in vivo data of
Lyrenas [47]. Simulations of the response to a 4 mg oral
dose of estradiol over predict with regard to Cmax and
AUC, although prediction of Tmax is robust. However,
examination of the in vivo data shows one individual
Fig. 3 Prediction of estradiol kinetics in women. Estradiol venous blood concentrations were simulated for the 1495-person virtual population
following a 0.3 mg i.v. bolus and b 2 mg or 4 mg oral bolus exposures, and presented as mean (±s.d.). The i.v. bolus data was compared to clinical data
from Kuhnz et al. [45], which is shown as mean (±s.d.), while oral dose simulations were compared to clinical data from Lyrenas et al. [47]
Table 1 Pharmacokinetic parameters for three models
In vivo PBPK PBPK-LiverODE PBPK-GSMN
i.v. – 0.3 mg AUC 10.2 ± 1.18 10.4 ± 0.23 6.1 ± 0.17 5.9 ± 0.56
Oral – 2 mg Tmax 3.8 ± 0.4 2.5 ± 0.34 3.5 ± 0.38 2.4 ± 0.18
Cmax 0.44 ± 0.24 0.34 ± 0.19 0.35 ± 0.24 0.32 ± 0.23
AUC 10.3 ± 1.18 8.9 ± 0.19 9.2 ± 0.13 8.1 ± 0.04
Oral – 4 mg Tmax 3.4 ± 0.6 3.1 ± 0.31 3.2 ± 0.35 2.3 ± 0.26
Cmax 0.63 ± 0.3 0.67 ± 0.25 0.71 ± 0.26 0.65 ± 0.21
AUC 13.4 ± 3.47 17.3 ± 0.38 17.4 ± 0.24 16.2 ± 0.09
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whose response to 4 mg oral estradiol is markedly differ-
ent, being closer to the response of those individuals ex-
posed to 2 mg oral estradiol. If this individual is
removed, then model prediction is within the error of
the in vivo data for both Cmax and AUC.
In addition to predicting estradiol plasma concentra-
tion, the model predicts concentration-time curves for
estradiol disposition into 16 tissue compartments. As
shown in Fig. 4a, IV dosing with 0.3 mg estradiol is pre-
dicted to increase concentrations in each compartment
at different rates, with Tmax values varying between
0.1 h {kidney} and 0.93 h {adipose} for the base PBPK
model. Clearance of estradiol through the kidney (CLeh)
and liver (CLint) results in a decrease in organ concen-
trations that is essentially complete by 15 h. The distri-
bution to, and clearance from, each organ is qualitatively
similar between the three models, but there are quanti-
tative differences. For example, predicted Cmax values
for the {liver} compartment is 50.3 nM, 7.9 nM and
75.7 nM for the PBPK, PBPK-LiverODE and PBPK-
GSMN models, respectively. We note that the fold-
difference in Cmax between the LiverODE model and
PBPK (6.4) or PBPK-GSMN (9.6) is consistent with the
difference in permeability-limited rate constants between
these systems (6.7-fold). Comparison of predicted organ
concentration against in vivo data is difficult due a lack
of robust in vivo data. Human data is not available, but
studies in rodents have been undertaken. Fig. 4b pre-
sents correlations between the predictions from each of
the models and the mouse disposition data of Benard et
al., where disposition of [18F]fluorinated-E2 was exam-
ined 1-h after i.v. dosing [48]. All three models success-
fully predict organ concentrations: RMSE is 4.9, 5.5, 3.4
for the PBPK, PBPK-LiverODE and PBPK-GSMN
models, respectively. The largest source of variation is in
the prediction of E2 concentration within the {gonads}
compartment. However, we note the substantial
variation in the literature for this measurement, with
plasma ratios ranging between 10 and 133. [48–51]. In
the current study the ratio is 49.7, 21.3 and 28.5 for the
PBPK, PBPK-LiverODE and PBPK-GSMN models,
respectively, and as such is consistent with the general
literature.
As described in the preceding paragraphs, all three
models perform acceptably using a range of metrics.
They are able to reproduce with an acceptable degree of
accuracy both clinical data and the predictions of the
other models. Where there are differences between the
model predictions, this may represent the different par-
ameter sets used within the models themselves or the
modelling framework used. Clearance from the liver is
represented by either a single ODE (CLint), a more com-
prehensive ODE-based model of estradiol metabolism in
the liver, or a genome-scale metabolic network. In each
case, the representation of biology has its uncertainties
based around model reduction, parameter robustness
etc. In addition, the PBPK and PBPK-ODE models are
simulated within COPASI, while the PBPK-GSMN
model is simulated in MuFINS. This may lead to differ-
ences in prediction due to the modelling software. Ex-
tensive comparison of model simulations in COPASI
and MuFINS suggests that overall model behaviours and
the magnitude of observed changes are consistent, but
that the exact timing of events may vary. This is most
likely due to the application of PNs in the MuFINS soft-
ware, whereby reactions are simulated through a pro-
pensity function that describes the probability that any
given transition will fire. Hence, for any given model the
same behaviour will occur regardless of the software
architecture, but the exact timing of an event may vary.
Impact of drug exposure on the metabolic phenotype
An important use of in silico models in drug develop-
ment is the prediction of interactions. Interaction with
therapeutic agents, exogenous chemicals (e.g. food com-
ponents/contaminants), or endogenous chemicals may
lead to a reduction in drug efficacy or increased risk of
toxicity. In addition, the metabolic adaptation that can
occur during chronic drug exposure may predispose in-
dividuals to an increased risk of disease development/
progression. Here, we explore the impact of chronic
phenytoin exposure on two endpoints; the clinically-
relevant interaction with estradiol, and the impact on
glucose secretion capacity in the liver.
The use of estrogens as both contraceptives and to
treat symptoms of the menopause means that individ-
uals are likely to be exposed for chronic periods. This
raises the possibility of concomitant exposure to other
drugs, and hence the potential for drug-drug interac-
tions. Traditionally, modelling drug-drug interactions
has involved a priori knowledge of the interaction, with
or without any underpinning mechanistic information.
The use of a genome-scale metabolic network has the
advantage that metabolite fluxes are based upon known
network connectivity and the production/consumption
of substrates/cofactors. As such, drug-drug interactions
should emerge from the simulation as a result of altered
fluxes within the metabolic network, without a priori
knowledge of the interaction [37]. This may improve the
ability to predict potential DDIs early in drug develop-
ment, allowing risk-benefit scenarios to be considered.
One scenario where clinically important drug-drug in-
teractions have been identified is during the concomitant
use of estrogens and antiepileptic drugs [52, 53]: this
scenario is especially important given the teratogenic li-
ability of several anticonvulsant drugs [54]. Nearly one-
fifth of fertile women with epilepsy use oral contracep-
tives, only slightly lower that than the overall population
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average of 25%, meaning that this is a significant consid-
eration for drug prescription [55]. To demonstrate how
a GSMN may aid prediction of DDIs we extended the
base PBPK-GSMN model to include PXR-mediated
induction of gene expression. PXR is a member of the
nuclear receptor family of ligand activated transcription
factors and regulates the gene expression of a range of
metabolic enzymes [39, 56]. The anticonvulsant pheny-
toin is a low affinity ligand for PXR [39, 57, 58], and ac-
tivates the expression of a range of proteins involved in
the metabolism of estrogens [39, 56]. As such, activation
of PXR is the mechanistic underpinning for the
phenytoin-estradiol DDI, as well as a large number of
other clinically important DDIs [59, 60]. A module
representing the activation of PXR by phenytoin, plus
the subsequent transcription and translation of 20 target
genes was developed, and is depicted in Fig. 5. These
target genes include phase I metabolic enzymes (e.g.
CYP3A4), phase II metabolic enzymes (e.g. GSTA1), and
drug transporters (e.g. ABBC3). While this is not an
Fig. 4 Prediction of estradiol organ distribution. a estradiol organ concentrations were simulated over 15 hours following a 0.3mg i.v. bolus.
b Predicted organ concentrations 1 hour following a 0.3mg i.v. bolus are compared to experimental data from the mouse, presented as mean
(+/- s.d.) [48]
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exhaustive list of all direct PXR target genes, and ex-
cludes indirect target genes and inhibition of expression,
it is interesting to note that it maps to 173/7440 (2.3%)
reactions within Recon2. As detailed in the Additional
file 1, where possible kinetic parameters are based upon
literature values and have been previously published
[61]. We note that we use an approach analogous to
PBPK model construction, whereby a generic model may
be tailored through the use of chemical-specific
parameters. Here, we use a previously published ODE-
based model of the transcriptional effects of PXR, with
rifampicin as the modelled ligand [61]. This model is al-
tered to represent phenytoin-mediated induction by
changing the parameters representing Kd between ligand
and PXR. Such an approach presumes that the down-
stream effects of PXR activation are analogous between
the two ligands, a reasonable starting assumption unless
evidence exists to the contrary. Predictions from the
Fig. 5 Activation of PXR-mediated gene expression. To represent drug-drug interactions, a kinetic model of PXR-mediated gene expression was generated,
based upon Kolodkin et al. [61]. The nuclear receptor PXR is activated by the low affinity ligand Phenytoin (P), forming PXRL. This increases transcription of
20 PXR target genes, leading to increased concentrations of the encoded target proteins. Predicted fold-inductions of CYP3A mRNA and protein are
consistent with data from Luo et al. [58]. n.d. = not determined. These target proteins are mapped to reactions within the Recon2 genome scale metabolic
network, with their concentration setting reaction bounds within the network. This results in an altered metabolic capacity within the network, leading to
increased estradiol (E) metabolism
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resultant model were compared to the experimental data
of [58].
Exposure of cells to 2, 10 or 20μM phenytoin results in
a fold induction (±s.d.) of 0.9 (±0.26), 1.6 (±0.29) and 2.2
(±0.25) in CYP3A mRNA, respectively. As shown in Fig. 5,
these values are consistent with fold increases predicted
by the model. Under normal therapeutic use, the steady-
state blood concentration of phenytoin is in the range 10-
20μg/ml, which is equivalent to 40–80μM. We therefore
undertook simulations under these conditions, with
CYP3A transcripts predicted to increase from 0.067 nM
to 0.21 nM and 0.28 nM, while concentration of the
encoded protein is predicted to rise from 111 nM to
351.5 nM and 467.9 nM, respectively; these are equivalent
to 3.2–fold and 4.2–fold inductions. This increase in pro-
tein expression is reflected in the GSMN through altered
bounds for all mapped reactions. For example, the
CYP3A4 protein is mapped to nine reactions within the
Recon2 GSMN, including the metabolic conversion of es-
tradiol to its catecholamine metabolites (R_RE3013C and
R_RE3013R). Under basal conditions, where CYP3A4 pro-
tein concentration is 111 nM, flux bounds for these reac-
tions are 0,0.23 (LB < UB), reflecting an irreversible
reaction. Activation of PXR results, and thus increased
CYP3A4 protein levels, increases the UB to 0.48 and 0.58
at 351 nM and 467 nM, respectively (Fig. 5). It should be
noted that this increases the bounds of the reactions, but
does not necessarily increase flux through these reactions;
this will only occur if the previous bound was limiting
with respect to maximisation of the objective function. In
the case of estradiol metabolism, these flux bounds are
limiting, as the predicted flux for metabolism of estradiol
by CYP3A4 increases from 0.23 to 0.48 and 0.58 as the
bounds increase (Additional file 1: Figure S6).
The impact of concomitant exposure to phenytoin and
oral estradiol is shown in Fig. 6. Simulations are carried
out assuming chronic administration of phenytoin,
meaning that phenytoin-mediated changes in protein
levels have reached a steady-state. Initial levels of PXR
target genes (mRNA and protein) are set to 0.21/
351.5 nM and 0.28/467.9 nM for 40μM and 80μM
phenytoin scenarios, respectively, compared to 0.067
/111 nM in the non-induced condition. Initially, we ex-
amined the impact of phenytoin co-exposure on the re-
sponse to a single oral dose of estradiol. Estradiol is
commonly prescribed at doses equivalent to 0.5 mg/day,
1 mg/day and 2 mg/day, and at all three dose levels con-
comitant exposure to phenytoin is predicted to alter es-
tradiol kinetics (Fig. 6). Tmax values do not alter,
remaining at just over two hours, but there are signifi-
cant decreases in Cmax and AUC. On average, estradiol
plasma AUC values decrease to 56%, 54% and 53%
(0.5 mg, 1 mg and 2 mg estradiol, respectively) with con-
comitant exposure to 40μM phenytoin. These further
decrease to 47%, 47% and 46% with 80μM phenytoin.
These values are consistent with the approximate 50%
decrease reported in the literature [52, 62].
Estradiol is most likely to be prescribed over a chronic
period of time when used as an oral contraceptive. We
therefore examined the impact of concomitant pheny-
toin exposure on such a scenario. As before, initial con-
ditions of PXR activation and target gene expression
were set for 0μM, 40μM and 80μM phenytoin to reflect
an individual already on therapy. Simulations were then
undertaken for a 10-day period where estradiol was ad-
ministered as an oral dose of 0.5 mg/day, 1 mg/day or
2 mg/day. As shown in Fig. 7, a once-a-day dosing re-
gime is sufficient to achieve a steady state exposure to
estradiol. There is a significant intra-day variability, with
peak and trough concentrations varying by approxi-
mately 2-fold for all exposures. Concomitant exposure
to phenytoin is predicted to produce a similar fold-
decrease in AUC as seen for the single oral dose, being
approximately 55% and 47% of the control value for
40μM and 80μM phenytoin, respectively. Trough plasma
estradiol concentrations are also predicted to decrease
by a similar level (Fig. 7).
The impact of chronic drug exposure is unlikely to be
limited to drug-drug interactions, with a current chal-
lenge being to predict the potential long-term adverse
health impacts of such chronic exposure. To explore
this, we examined sample steady-state flux distributions
within the GSMN under both basal (i.e. no phenytoin)
and 80μM phenytoin exposure scenarios. Under basal
conditions, a maximal rate of glucose secretion of 6.8
mmole/g dry weight/h was predicted. In contrast,
chronic exposure to 80μM phenytoin was predicted to
increase this to 7.2 mmole/g dry weight/h. A full list of
reaction fluxes for each scenario is provided as
Additional file 2: 1032 reactions are different between
the two sample solutions, representing approximately
14% of the total reaction in the GSMN. It should be
noted, however, that some of these differences are likely
to represent technical artefacts where the solver can
identify two flux distributions that reach the same opti-
mal solution. These alternate solutions may represent
the known redundancy in biological networks, which
contributes to the overall robustness of the system. Re-
gardless, this supports the notion that drugs can have
large-scale impacts on metabolic systems. It should be
noted that while we have used phenytoin as the drug in
this example, as the driver for metabolic adaptation is
activation of PXR then any PXR agonist could cause
these effects. Nuclear receptors, most notably PPARs,
have been linked to energy metabolism within the body,
but increasing evidence supports the role of a number of
other nuclear receptors [63, 64]. Increased levels of PXR
has been associated with metabolic syndrome, most
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commonly liver steatosis and obesity, but the mechanis-
tic rationale is unclear [65]. Here, we predict that in-
creased activation of PXR target genes can cause an
increased potential for glucose production from the liver,
an important driver of metabolic syndrome.
Conclusion
The central role of estrogens in mammalian biology is clear.
However, the complex nature of this biology, with multiple
factors impacting on estradiol kinetics and multiple bio-
logical targets effected by the hormone, raises an important
challenge with regard to predicting these effects. This is es-
pecially pertinent given the increasing concern about envir-
onmental exposure to endocrine disrupting compounds,
and the epidemiological evidence linking such exposure to
chronic conditions. PBPK modelling has traditionally been
used to predict drug disposition within individuals and pop-
ulations. Such models are informed by, and validated
through, experimental data, with a lack of correlation
highlighting areas for model refinement in a truly iterative
process [19, 66]. One advantage of such approaches is that
they do not try to model all potential interactions between
the drug and the body. Rather, they use a reductionist ap-
proach to reproduce the main emergent behaviours of the
system. However, this is also a disadvantage as mechanistic
detail is lost at the expense of model reduction. To balance
these pros and cons, we and others propose the addition of
biologically important, mechanistically-detailed hubs within
a more general reductionist model [17, 18]. To demonstrate
such an approach, we have expanded a classical PBPK
model of estradiol [20] in two distinct ways; First, through
the addition of a fully deterministic kinetic model of
Fig. 6 Impact of phenytoin on single oral dose estradiol kinetics in women. Estradiol venous blood concentrations were simulated for the 1495-
person virtual population following a 0.5 mg, b 1 mg, or c 2 mg oral estradiol. PXR occupancy, PXR target-gene mRNA and protein levels were set to
reflect concomitant exposure to 0μM, 40μM or 80μM phenytoin, as indicated. A representative concentration-time plot is shown in the left panel, with
AUC and Cmax (mean ± s.d.) presented in the middle and right panels, respectively. Statistical significance was assessed using a two-way ANOVA with
Sidak’s multiple comparison test. *** = p < 0.001 compared to 0μM phenytoin
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estrogen metabolism within the liver; second, through the
addition of a genome scale metabolic network to encompass
all metabolic pathways in the liver. We demonstrate that all
three models can reproduce experimental data on the
plasma kinetics of estradiol following both i.v. bolus and oral
exposures. The utility of these two approaches is then exam-
ined. Generation of a fully deterministic model for chemical
metabolism is time-consuming, as it requires the derivation
of robust parameters for all ODEs. This may not be possible
for all compounds, as full metabolic (and kinetic) profiling
will not have been undertaken. However, when generated,
such a model has the potential to underpin/inform the set-
ting of an intrinsic clearance term, predicting the contribu-
tion of different enzymes on the final clearance rate. In
addition, the extra mechanistic information also has the
potential to allow examination of specific scenarios, such as
the impact of genetic variation. In contrast to the time re-
quired to develop a mechanism-based deterministic model,
GSMNs are now available ‘off-the-shelf ’. In this case, the
challenge here has been that analysis of GSMNs has trad-
itionally relied upon the assumption of a steady-state, mean-
ing that the adaption of metabolic systems to chemical
exposure cannot be robustly modelled. Here, we use our
QSSPN approach to integrate a GSMN with both a PBPK
model and an ODE-based model of PXR-mediated gene ex-
pression. We demonstrate how these models can reproduce
a complex biological phenomenon, and one with important
clinical implications: drug-drug interactions. The central ad-
vantage of such an approach is that the DDI emerges from
the network connectivity captured by the GSMN, rather
Fig. 7 Impact of phenytoin on repeat oral dose estradiol kinetics in women. Estradiol venous blood concentrations were simulated for the 1495-
person virtual population following a 0.5 mg, b 1 mg, or c 2 mg oral estradiol. A representative concentration-time plot is shown in the left panel,
with AUC and trough concentration (mean ± s.d) presented in the middle and right panels, respectively. Statistical significance was assessed using
a two-way ANOVA with Sidak’s multiple comparison test. *** = p < 0.001 compared to 0μM phenytoin
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than having to be described explicitly. Essentially, the induc-
tion of PXR-target genes by phenytoin causes a change in
the flux bounds for a range of reactions within the GSMN.
As some of these reactions are related to estradiol, then its
metabolism may be impacted, which would lead to the
emergence of the DDI. An advantage of this approach is that
the alteration in bounds leads to the possibility of a DDI,
but does not necessarily determine that it will occur. If, for
example, estradiol metabolism was not limited by the
bounds set in the original GSMN then the induction would
be biologically silent as there was already sufficient capacity
in the system to meet the biological demand.
Finally, we demonstrate how this approach can be
used to explore the implications of chronic drug use.
Adaptation of metabolism to chemical exposure is a well
described phenomenon, and one that underpins the con-
cept of homeostasis. However, such adaptation often
comes at a biological cost, with some areas of metabol-
ism being deprioritised to meet the immediate metabolic
demand. If exposure to the drug is acute this may have a
limited impact, but upon chronic exposure this alter-
ation in metabolic landscape may have significant conse-
quences. For example, some of the adverse health effects
associated with chronic drug exposure are almost cer-
tainly due to such metabolic reprogramming [64, 65].
We believe that the use of these extended modelling ap-
proaches will allow more precise mechanistic questions to
be addressed, helping to interpret of complex biological
datasets. This will add significant biological insight to un-
derstanding drug actions on the body, and the factors that
may influence the emergent biological effect [67].
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